About Cevec Pharmaceuticals
Cevec Pharmaceuticals is a Healthcare company based in Koln (Germany) founded in 2001, and was acquired by Cytiva in October 2022. Provider of glyco-optimised human cell lines and gene therapy vectors using proprietary cell expression system. Cevec Pharmaceuticals has raised $28.43 million across 7 funding rounds from investors including Cytiva, NRW.Bank and Creathor Venture. The company has 39 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Proteomics. Its legal entity is CEVEC Pharmaceuticals GmbH.
Company details
Cevec Pharmaceuticals was founded in 2001 and is based in Cologne, Germany. Operations focus on the biotechnology sector, where glyco-optimized human suspension cell lines are developed for recombinant protein glycosylation through the CAP Go expression platform. Gene therapy vectors are produced using the scalable CAP GT system and ELEVECTA technology for AAV manufacturing. Cell line development and protein expression services are also offered to support research and production needs.
Funding Insights of Cevec Pharmaceuticals
Cevec Pharmaceuticals has successfully raised a total of $28.43M across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.43M
- Total Rounds 7
- First Round $5.9M
(Nov 2009)
- Investors Count 5
All 7 funding rounds of Cevec Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | Series E | – | – | – | |
| Apr 2019 | Series D | – | – | – | |
| Jul 2015 | $4.89M | Series C | – | – | |
| Oct 2012 | $3.64M | Series C | – | – | |
| Jul 2011 | $8.6M | Series B | – | – | |
| Feb 2010 | $5.4M | Series B | – | – | |
| Nov 2009 | $5.9M | Series B | – | – |
6 investors in total: 6 institutional.
Investors in Cevec Pharmaceuticals
Cevec Pharmaceuticals has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Cytiva, NRW.Bank and Creathor Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| creathor.com | ||||
Venture capital investments are made in life science innovations. | 2000 | pvp.health | Berlin, Germany | |
Loans, advice, seminars, and networks are provided for financial support. | 2001 | nrwbank.de | Dusseldorf, Germany | |
Midas Group is engaged in construction and retail fit-out services. | 1976 | midasgroup.co.uk | Bristol, United Kingdom | |
Sparkasse is recognized as a leading German savings bank network. | sparkasse.de | Germany | ||
Life science software and research products are provided online. | 1968 | cytivalifesciences.com | Sheffield, United Kingdom |
Investor details for Cevec Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cevec Pharmaceuticals
4 people are tracked at Cevec Pharmaceuticals (4 in leadership); the tracked headcount is 39.
| Name | Role | Group |
|---|---|---|
Nicole Faust | Managing Director | Leadership |
Ulrich Kettling | VP, Commercial | Leadership |
Nikola Strempel | VP, Cell Line & Process Development | Leadership |
Markus Krieger | VP, Technology Development | Leadership |
Complete people profiles for Cevec Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cevec Pharmaceuticals
4 dated milestones of Cevec Pharmaceuticals across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Cevec Pharmaceuticals is founded.
- Funding First funding round of $5.9M.
- Funding Latest funding round, Series E,.
- Exit Acquired by Cytiva.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cevec Pharmaceuticals
Complete news archive for Cevec Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cevec Pharmaceuticals
Cevec Pharmaceuticals was founded in 2001 and raised its 1st funding round 8 years after it was founded.
Cevec Pharmaceuticals is headquartered in Koln, Germany. It is registered at Koln, North Rhine-westphalia, Germany.
Cevec Pharmaceuticals is a funded company, having raised a total of $28.43M across 7 funding rounds to date. The company's 1st funding round was a Series B of $5.9M, raised on Nov 2009.
Cevec Pharmaceuticals has 39 employees.
Cevec Pharmaceuticals was founded in 2001 and is based in Cologne, Germany. Operations focus on the biotechnology sector, where glyco-optimized human suspension cell lines are developed for recombinant protein glycosylation through the CAP Go expression platform. Gene therapy vectors are produced using the scalable CAP GT system and ELEVECTA technology for AAV manufacturing. Cell line development and protein expression services are also offered to support research and production needs.
Cevec Pharmaceuticals has 6 investors. Key investors include Cytiva, NRW.Bank, Creathor Venture, Peppermint Venture Partners, and Midas Group.
Cevec Pharmaceuticals operates through Cevec Pharmaceuticals Gmbh.
Yes. Cevec Pharmaceuticals was acquired by Cytiva in October 2022.